Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push 
Amazon Explores AI Content Marketplace With Media Publishers 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
NEW YORK, April 03, 2018 -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focusing on the development of innovative cancer therapies, today announced that the Company has filed its annual report on Form 20-F for the fiscal year ended December 31, 2017 with the U.S. Securities and Exchange Commission on April 03, 2018. The annual report can be accessed on the Company’s investor relations website at http://ir.beyondspringpharma.com.
The Company will provide a hard copy of its annual report containing its audited consolidated financial statements, free of charge, to its shareholders upon request. Requests should be directed to Investor Relations, BeyondSpring Inc., 28 Liberty Street, 39th Floor, New York, NY 10005 USA.
About Plinabulin
Studies on Plinabulin's method of action indicate that Plinabulin activates GEF-H1, a guanine nucleotide exchange factor. GEF-H1 activates downstream transduction pathways leading to the activation of the protein c-Jun. Activated c-Jun enters the nucleus of dendritic cells to upregulate immune-related genes, which contributes to the up-regulation of a series of genes leading to dendritic cell maturation, T-cell activation and other effects that prevent neutropenia.
About BeyondSpring
BeyondSpring is a global, clinical-stage biopharmaceutical company developing innovative immuno-oncology cancer therapies with a robust pipeline from internal development and from collaboration with University of Washington in de novo drug discovery using ubiquitination platform. BeyondSpring’s lead asset, Plinabulin, is in a Phase 3 global clinical trial as a direct anticancer agent in the treatment of non-small cell lung cancer (NSCLC) and two Phase 2/3 clinical programs in the prevention of chemotherapy-induced neutropenia (CIN). BeyondSpring has a seasoned management team with many years of experience bringing drugs to the global market.
Contact:
Media Relations:
Caitlin Kasunich / Amy Singh
KCSA Strategic Communications
212.896.1241 / 212.896.1207
[email protected] / [email protected]
Investor Relations:
Laura Perry / Joseph Rayne
Argot Partners
212.600.1902
[email protected]
